MiMedx Group (NASDAQ:MDXG) Cut to “Buy” at Wall Street Zen

Wall Street Zen downgraded shares of MiMedx Group (NASDAQ:MDXG) from a strong-buy rating to a buy rating in a research report released on Saturday.

MDXG has been the subject of a number of other research reports. Citizens Jmp initiated coverage on shares of MiMedx Group in a research report on Monday, February 23rd. They set a “market outperform” rating and a $10.00 price target for the company. UBS Group set a $10.00 price objective on shares of MiMedx Group in a research note on Monday, February 23rd. Lake Street Capital dropped their target price on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Citigroup began coverage on shares of MiMedx Group in a research note on Monday, February 23rd. They issued a “market outperform” rating on the stock. Finally, Mizuho decreased their price target on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, December 17th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.60.

MiMedx Group Stock Down 0.2%

Shares of NASDAQ MDXG opened at $4.88 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.92 and a current ratio of 4.32. MiMedx Group has a 1 year low of $4.71 and a 1 year high of $8.43. The stock’s 50-day simple moving average is $5.65 and its 200-day simple moving average is $6.55. The firm has a market cap of $725.01 million, a price-to-earnings ratio of 15.25 and a beta of 1.59.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.The firm had revenue of $118.10 million during the quarter, compared to the consensus estimate of $106.78 million. As a group, equities analysts anticipate that MiMedx Group will post 0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MiMedx Group

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in MiMedx Group in the fourth quarter valued at approximately $78,000. Invesco Ltd. lifted its holdings in shares of MiMedx Group by 5.9% in the 4th quarter. Invesco Ltd. now owns 84,824 shares of the company’s stock worth $574,000 after purchasing an additional 4,708 shares during the last quarter. Corient Private Wealth LLC lifted its holdings in shares of MiMedx Group by 26.0% in the 4th quarter. Corient Private Wealth LLC now owns 46,658 shares of the company’s stock worth $316,000 after purchasing an additional 9,614 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its position in MiMedx Group by 33.7% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 20,786 shares of the company’s stock valued at $141,000 after purchasing an additional 5,236 shares during the period. Finally, EP Wealth Advisors LLC bought a new position in MiMedx Group during the 4th quarter worth $156,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.